Evidence map›Paper›PMID 28293015›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2017

Profile of Expression of Genes Encoding Matrix Metallopeptidase 9 (MMP9), Matrix Metallopeptidase 28 (MMP28) and TIMP Metallopeptidase Inhibitor 1 (TIMP1) in Colorectal Cancer: Assessment of the Role in Diagnosis and Prognostication.

Zbigniew Lorenc, Dariusz Waniczek, Katarzyna Lorenc-Podgórska, Wiktor Krawczyk, Maciej Domagała, Mateusz Majewski, Urszula Mazurek

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Low Serum Levels of miR-101 Are Associated with Poor Prognosis of Colorectal Cancer Patients After Curative Resection.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  15. Identification and Interaction Analysis of Molecular Markers in Colorectal Cancer by Integrated Bioinformatics Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zbigniew LorencChair and Clinical Department of General, Colorectal and Trauma Surgery, Medical University of Silesia, Sosnowiec, Poland.
Dariusz WaniczekDepartment of Propaedeutics Surgery, Chair of General, Colorectal and Polytrauma Surgery, Medical University of Silesia, Katowice, Poland.
Katarzyna Lorenc-PodgórskaChair and Clinical Department of General, Colorectal and Trauma Surgery, Medical University of Silesia, Katowice, Poland.
Wiktor KrawczykChair and Clinical Department of General, Colorectal and Trauma Surgery, Medical University of Silesia, Katowice, Poland.
Maciej DomagałaChair and Clinical Department of General, Colorectal and Trauma Surgery, Medical University of Silesia, Katowice, Poland.
Mateusz MajewskiChair and Clinical Department of General, Colorectal and Trauma Surgery, Medical University of Silesia, Katowice, Poland.
Urszula MazurekDepartment of Molecular Biology, Medical University of Silesia, Katowice, Poland.
Medical University of Silesia · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Studies on the pathomechanism of colorectal cancer (CRC) expansion indicate a significant role of metalloproteinases and their inhibitors in the extracellular matrix. The results of the analysis of a profile of transcriptional activity of genes encoding metalloproteinases were the basis of the hypothesis indicating changes in the expression of genes encoding MMP9, MMP28, and TIMP1 as an additional diagnostic and prognostic marker of CRC. MATERIAL AND METHODS The material consisted of samples obtained from resected tumors and healthy tissue samples from 15 CRC patients (aged 46-72 years) at clinical stages (CSs) I and II-IV. Gene expression analysis was done using microarrays. Microarray data analysis was done using the GeneSpring 11.5 platform. The results were validated using the qRT-PCR technique. RESULTS We found high levels of expression of MMP9 at each CS, as well as in the tissues at the early stage of CRC. Additionally, we observed high levels of expression of TIMP1 and low levels of MMP28 genes in CS II-IV. No statistically significant differences based on the stage of CRC were observed. CONCLUSIONS MMP9 gene profile may be a complementary diagnostic marker in CRC. The results suggest a crucial role of MMP9 at the early stage of carcinogenesis in the large intestine. The increase in MMP9 and TIMP1 mRNA concentration and the decrease in MMP28 in the large intestinal tissue may be a confirmation of cancer, but it may not indicate the advance of CRC.

Indexed as

AgedBiomarkers, TumorCase-Control StudiesColorectal NeoplasmsFemaleHumansMaleMatrix Metalloproteinase 9Matrix Metalloproteinases, SecretedMiddle AgedPrognosisRNA, MessengerTissue Inhibitor of Metalloproteinase-1Biomarkers, TumorMatrix Metalloproteinase 9Matrix Metalloproteinases, SecretedMMP28 protein, humanMMP9 protein, humanRNA, MessengerTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1

Identifiers

PMID28293015
PMCPMC5363457
OpenAlexW2603927402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.